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Congestion is a major reason for hospitalization in acute heart failure (HF). Therapeutic strategies to manage congestion include diuretics,
vasodilators, ultrafiltration, vasopressin antagonists, mineralocorticoid receptor antagonists, and potentially also novel therapies such as gut
sequesterants and serelaxin. Uncertainty exists with respect to the appropriate decongestion strategy for an individual patient. In this review,
we summarize the benefit and risk profiles for these decongestion strategies and provide guidance on selecting an appropriate approach for
different patients. An evidence-based initial approach to congestion management involves high-dose i.v. diuretics with addition of vasodilators
for dyspnoea relief if blood pressure allows. To enhance diuresis or overcome diuretic resistance, options include dual nephron blockade
with thiazide diuretics or natriuretic doses of mineralocorticoid receptor antagonists. Vasopressin antagonists may improve aquaresis and
relieve dyspnoea. If diuretic strategies are unsuccessful, then ultrafiltration may be considered. Ultrafiltration should be used with caution in
the setting of worsening renal function. This review is based on discussions among scientists, clinical trialists, and regulatory representatives
at the 9th Global Cardio Vascular Clinical Trialists Forum in Paris, France, from 30 November to 1 December 2012.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Keywords Acute heart failure • Decongestion • Volume overload • Strategies • Outcomes
Introduction
Heart failure (HF) is a major and increasing public health problem
worldwide.1–3 The primary reason for acute HF (AHF) hospital-
ization is congestion manifested by dyspnoea, oedema, and fatigue
due to elevated filling pressures.4–6 Despite inpatient treatment
targeting decongestion with diuretics, many patients are discharged
without weight loss and with persistent signs of congestion.7,8 For
instance, in an international AHF trial, persistent congestion was
present at discharge in more than a quarter of patients.9 Baseline
congestion and residual congestion at discharge are associated with
increased rehospitalization and mortality, and successful deconges-
tion is a major goal of AHF management.9–11
Uncertainty exists with respect to the pathogenesis of con-
gestion and how best to treat congestion prior to discharge.12,13
In addition to diuretics, strategies to treat congestion include
vasodilators, ultrafiltration (UF), vasopressin antagonists, and
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.. mineralocorticoid receptor antagonists (MRAs). Serelaxin and gut
sequesterants may also be used for decongestion in the future.
Here, we summarize the benefit and risk profiles for these ther-
apies and provide guidance on selecting an appropriate approach
for different patients. This review is based on discussions among
scientists, clinical trialists, and regulatory representatives at the
9th Global CardioVascular Clinical Trialists Forum in Paris, France,
from 30 November to 1 December 2012.
Pathophysiology of congestion
in acute heart failure
Congestion is defined as a high LV end-diastolic pressure associated
with signs and symptoms such as dyspnoea, rales, and oedema
(Figure 1).13 Recent data also demonstrate the importance of
elevation in right-sided pressures as characterized by inferior
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Figure 1 Pathophysiology of congestion. JVD, jugular venous distension; LA, left atrial; LVDP, left ventricular diastolic pressure; PA, pulmonary
artery; PCWP, pulmonary capillary wedge pressure; RA, right atrial; RV, right ventricular. Reproduced, with permission, from Gheorghiade
et al. Eur J Heart Fail 2010;12:423–433.13
vena cava dilation,14 which result in the characteristic signs and
symptoms of hepatic and renal congestion.
At present, the underlying mechanisms of congestion in AHF are
poorly understood. The traditional paradigm assumes that haemo-
dynamic abnormalities related to reduced cardiac output and acti-
vation of the renin–angiotensin–aldosterone system (RAAS) are
the primary pathophysiological drivers in AHF. Underlying car-
diac dysfunction is exacerbated by coronary ischaemia, hyperten-
sion, arrhythmia, infection, or medical/dietary non-adherence, with
increased fluid retention. However, in many patients, a specific
precipitating factor cannot be identified, and early symptoms of
congestion occur without significant weight gain.15 Thus, there is
increasing recognition that fluid redistribution may contribute to
AHF. For instance, extracellular fluid volume can shift from the
splanchnic veins into the effective circulating blood volume during
AHF via autonomic mechanisms.16 Contemporary data also sup-
port a role for inflammation, endothelial cell activation, prothrom-
botic changes, and abnormalities in arginine vasopressin (AVP)
and adenosine signalling (Figure 2).17 For instance, Colombo and
colleagues recently demonstrated that peripheral venous conges-
tion caused the release of inflammatory mediators and changes in
endothelial cell response in an experimental model.18 The contri-
bution of these mechanisms in different AHF patients varies.19 For
instance, elderly females with preserved EF tend to present more
often with rapidly progressive pulmonary oedema in the setting of
hypertension related to mechanisms of reduced arterial compli-
ance and venous capacitance.20–22 Other patients present with a ..
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.. distinct phenotype characterized by the insidious onset of dysp-
noea, and peripheral oedema with evidence of hepatic and renal
dysfunction due, in part, to RAAS activation, inflammation, and
progressive cardiorenal syndrome.17,23–25 Regardless of the spe-
cific underlying mechanisms for an individual patient, congestion
contributes to HF progression through further neurohormonal
activation, LV geometric changes, pulmonary hypertension, right
ventricular (RV) dysfunction, and adverse cardiorenal changes.26–28
Assessment of congestion
and decongestion
The pattern of congestion in AHF varies, but data suggest that 89%
of patients present with dyspnoea; rales and peripheral oedema are
present in 68% and 66%, respectively.4 While there is not currently
a standardized definition of adequate decongestion, clinical trials
have used the following criteria: jugular venous distension (JVD)
<8 cm of water, no more than trace peripheral oedema, and
the absence of orthopnoea.29 These criteria have been simplified
into an ‘orthoedema’ congestion score based on the presence of
orthopnoea (≥2 pillow= 2,<2 pillows= 0) and peripheral oedema
(trace = 0, moderate = 1, severe = 2) with the components added
to classify congestion as mild (score 0–1), moderate (2), and severe
(3–4).30 A post-hoc analysis of the DOSE-HF and CARRESS-HF
trials of AHF patients with congestion (and cardiorenal syndrome
in the case of CARRESS-HF) found that baseline orthoedema
was moderate in 22% of patients and severe in 62%.31 Following
© 2014 The Authors
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Figure 2 The underlying pathophysiological mechanisms of volume overload in acutely decompensated heart failure. AVP, arginine
vasopressin; GFR, glomerular filtration rate; NO, nitric oxide; RAAS, renin–angiotensin–aldosterone system; ROS, reactive oxygen species;
SNS, sympathetic nervous system. Reproduced, with permission, from Koniari et al. Eur Heart J Acute Cardiovasc Care 2012;1:256–268.17
aggressive inpatient therapy targeting decongestion, more than
one-third of patients (35%) had persistent moderate to severe
congestion at discharge. Higher orthoedema scores at admission
and discharge were both associated with increased risk for 60-day
death or HF hospitalization.
These recent studies in combination with other data in AHF
patients demonstrate that even with severe haemodynamic con-
gestion, physical signs including rales, oedema, and JVD may have
limited sensitivity and specificity.32 Moreover, markers of decon-
gestion such as weight and fluid loss have a poor correlation with
dyspnoea relief.33 Given the difficulty in accurately assessing con-
gestion by exam, biomarkers and other novel approaches may
help clinicians to quantify congestion. For example, recent data
highlight a role for the use of bioimpedance techniques in eval-
uating volume status.34 Natriuretic peptides are the most com-
monly used biomarker of volume status. Rather than using abso-
lute thresholds of natriuretic peptides to signify congestion, the
value of using ‘wet’ and ‘optivolaemic’ values for individual patients
has been demonstrated.35 In other words, clinicians may consider
obtaining serial values (e.g. on admission for AHF with conges-
tion, prior to discharge from AHF following decongestion, and
during a period of euvolaemia as an outpatient) in order to inform
future clinical evaluation of an individual patient’s congestion sta-
tus. Haemoconcentration during hospitalization, as characterized
by increases in haemoglobin or haematocrit, albumin, and total
protein, represents another marker of decongestion. Haemocon-
centration during AHF hospitalization has been associated with
improved 180-day survival36 despite an association with worsening .
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.. renal function (WRF).37 Recent evidence has also highlighted the
importance of the timing of haemoconcentration.38 Only haemo-
concentration that occurs later during hospitalization is associated
with improved outcomes, which suggests the importance of sus-
tained decongestion. Altogether, the assessment of volume status
is of paramount importance in order to tailor therapies to an
individual patient’s needs. In contemporary clinical practice, the
assessment of volume status is largely based on data from clini-
cal examination and laboratory biomarker profiles. Future work
will better define the role of novel techniques to monitor volume
status such as bioimpedence and implantable monitors.
Decongestion strategies
Loop diuretics
Historically, loop diuretics (e.g. furosemide and torsemide)
have been the cornerstone of decongestive therapy.39 Loop
diuretics inhibit the renal Na+/2Cl– /K+ co-transporter, result-
ing in natriuresis and diuresis. In HF patients, the diuretic
dose–response curve shifts downward and to the right, such
that a higher dose is required to achieve the effect. Loop diuret-
ics generally improve dyspnoea and decrease ventricular filling
pressures in AHF (Figure 3). Several small studies of torsemide vs.
furosemide40–42 and a recent meta-analysis43 suggest a decrease
in HF morbidity with torsemide compared with furosemide.
However, a prospective large-scale trial is needed to support these
findings.
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Figure 3 Diuretic mechanisms. Proposed positive and negative effects of loop diuretics as well as sites of action for thiazide diuretics and
natriuretic doses of aldosterone antagonists. CHF, congestive heart failure; MR, mitral regurgitation; RAAS, renin–angiotensin–aldosterone
system. Reproduced, with permission, from Felker and Mentz. J Am Coll Cardiol 2012;59:2145–2153.39
The DOSE trial (Diuretic Optimization Strategies Evaluation) is
the largest randomized AHF trial to evaluate diuretic strategies.44
DOSE randomized 308 AHF patients to i.v. furosemide given as
boluses or continuous infusion and to either a low-dose (i.v. dose
numerically equivalent to the patient’s oral dose) or a high-dose
(2.5 times the oral dose given intravenously) strategy. There was
no significant difference in the co-primary endpoints of global
assessment of symptoms or change in serum creatinine over 72
h with any of these strategies. However, patients randomized to
the higher dose strategy had more favourable outcomes for the
secondary measures of dyspnoea relief, change in weight, and fluid
loss. However, as noted above, more than one-third of patients in a
combined analysis of the DOSE and CARRESS trials had persistent
congestion at discharge despite therapy targeting decongestion in
the clinical trial setting.31 Thus, despite the efficacy of loop diuretics
for dyspnoea relief, data suggest limitations related to successful
decongestion.
Loop diuretic use is also balanced by limitations of diuretic resis-
tance, neurohormonal activation, and WRF.39 Diuretic resistance
occurs when these agents fail to control volume status adequately .
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. despite appropriate dose escalation. Mechanisms of diuretic resis-
tance include the ‘braking phenomenon’, ‘rebound’ effect, and
hyperaldosteronism. The ‘braking phenomenon’ occurs when long-
term diuretic use results in a reduced natriuretic response due,
in part, to nephron adaptations.45 The ‘rebound’ effect involves
post-diuretic sodium retention typically in the setting of inadequate
dosing frequency and insufficient sodium restriction.46 Sequential
nephron blockade with thiazide-type diuretics may be used in com-
bination with loop diuretics to augment diuresis.47 However, their
use has been associated with increased arrhythmia risk due to
hypokalaemia.48
Observational studies have shown associations between
high-dose loop diuretics and adverse outcomes.49–51 However,
these studies are confounded, since patients receiving higher
doses of diuretics tend to have greater disease severity and/or
co-morbidity. Nonetheless, animal studies have shown that
treatment with furosemide results in progression of LV systolic
dysfunction.52 Potential mechanisms for worse outcomes with
loop diuretics include RAAS activation, electrolyte disturbances,
and WRF.
© 2014 The Authors
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Loop diuretics may cause RAAS activation. Studies supporting
this concept, however, generally pre-date contemporary HF phar-
macotherapy. A retrospective study of the SOLVD trial demon-
strated that plasma renin activity (PRA) was significantly ele-
vated in HF patients receiving diuretics compared with those
not receiving diuretics.53 In another study, acute dosing of i.v.
furosemide resulted in rapid PRA elevation in HF patients treated
chronically with digoxin, and this was associated with systemic
vasoconstriction.54
The association between higher diuretic dosing and WRF has
been of particular interest given that WRF is associated with
worse outcome.49,55 However, recent data have suggested that
transient WRF during AHF therapy may not affect post-discharge
outcomes.37,56 For instance, in the DOSE trial, higher dose diuretics
were superior to lower dose diuretics for dyspnoea relief and
fluid loss at the cost of transient WRF that did not appear to
have long-term consequences.44 Given that persistent congestion
is associated with WRF57 and adverse events, transient WRF
may be a reasonable trade-off for decongestion. For instance, a
recent analysis by Metra et al. demonstrated that WRF was not
associated with worse outcomes, but that WRF in the context
of persistent congestion was an independent predictor of post-
discharge morbidity and mortality.58
Vasodilators
Current guidelines indicate that if symptomatic hypotension is
absent during hospitalization for AHF, i.v. vasodilators may be con-
sidered as an adjuvant to diuretic therapy for dyspnoea relief.1,3
There are currently no data to support improved outcomes in AHF
patients treated with vasodilators. Overall, the data support mod-
est beneficial effects on dyspnoea relief and haemodynamics (e.g.
central venous pressure and pulmonary capillary wedge pressure),
but further details related to effects on peripheral oedema, net fluid
loss, and weight loss are limited. Thus, further characterization of
the utility of these agents to decongest patients adequately based
on the metrics above is not possible.
Intravenous nitroglycerin is primarily a venodilator that lowers
preload and may help reduce pulmonary congestion.59 However,
tachyphylaxis to nitroglycerin may develop within hours despite
dose escalation.60 Nitroprusside is a balanced venodilator and arte-
riodilator with effects on the pulmonary vasculature.61 Efficacy
data with nitroprusside in AHF patients are limited and largely
confined to post-myocardial infarction LV dysfunction.62,63 Nitro-
prusside use is typically confined to an intensive care setting with
invasive haemodynamic monitoring due to the potential for marked
hypotension.1
Nesiritide reduces ventricular filling pressures, yet studies
demonstrated variable effects on dyspnoea relief. A randomized
trial of nesiritide vs. placebo in 127 AHF patients demonstrated
that nesiritide more rapidly reduced dyspnoea compared with
diuretics alone.64 The VMAC study investigated the use of nesiri-
tide vs. nitroglycerin vs. placebo in 489 AHF patients.65 Nesiritide
resulted in significant improvements in wedge pressure com-
pared with nitroglycerin and placebo. However, there was no
difference between nesiritide and nitroglycerin with respect to ..
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.. dyspnoea benefits. ASCEND-HF demonstrated that nesiritide
compared with placebo had a modest non-significant impact on
dyspnoea at the cost of more hypotension.66 Nesiritide did not
affect post-discharge outcomes. A recent subgroup analysis also
showed that nesiritide did not increase urine output compared
with standard therapy.67 Thus, routine use of nesiritide has not
been recommended in the broad AHF population.
Novel natriuretic peptides with vasodilatory effects, such as
ularitide, are being investigated in acute HF patients. Two double-
blind placebo-controlled proof-of-concept studies demonstrated
haemodynamic and symptom benefits with ularitide.68 An ongoing
phase III trial of ularitide is investigating a potential role for ularitide
added to standard therapy in acute HF (NCT01661634).
Ultrafiltration
Ultrafiltration involves removal of plasma water across a semi-
permeable membrane in response to a transmembrane pressure
gradient.39 If fluid removal does not exceed the interstitial fluid
mobilization rate, then intravascular volume can be preserved,
potentially avoiding RAAS activation and WRF.39 However, most
studies investigating RAAS activation with UF pre-dated routine
use of beta-blockers and ACE inhibitors.
The UNLOAD trial was the first large-scale trial of UF in AHF.69
This unblinded trial randomized 200 patients with AHF to either
UF or loop diuretics as the primary decongestive therapy within 24
h of hospitalization. The duration and rate of UF were decided by
the treating physicians. The co-primary endpoints were weight loss
and dyspnoea relief at 48 h. The UF group had greater weight loss
(mean of 5.0 kg vs. 3.1 kg, P = 0.001), but there was no difference in
dyspnoea relief. There was significantly less hypokalaemia with UF,
and other safety parameters (including serum creatinine change)
were similar in the two study arms. Net fluid loss at 48 h (a
secondary endpoint) was also greater in the UF arm (mean of
4.6 L vs. 3.3 L, P = 0.001). However, BNP improvements were
similar with UF and usual care. There was a significant decrease
in the secondary endpoint of rehospitalization for HF at 90 days
with UF compared with diuretic therapy (Figure 4). These findings
Figure 4 Freedom from heart failure rehospitalization.
Kaplan–Meier estimate of freedom from rehospitalization
for heart failure within 90 days after discharge in the ultra-
filtration (red line) and standard care (blue line) groups.
Reprinted, with permission, from Costanzo et al. J Am Coll Cardiol
2007;49:675–683.69
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are hypothesis-generating given the small number of events, short
follow-up, and unblinded study design.
CARRESS-HF was a randomized trial of UF vs. stepped pharma-
cological therapy in 188 AHF patients with WRF and persistent
volume overload.29 UF was performed at a fluid removal rate of
200 mL/h. Stepped pharmacological therapy involved adjustments
in loop diuretic doses as well as i.v. vasodilators and inotropic
agents as a function of the signs and symptoms of congestion, urine
output, blood pressure, EF, and the presence or absence of RV
failure at 48 h. CARRESS-HF tested UF in a different patient popu-
lation (i.e. cardiorenal syndrome type 1) compared with UNLOAD
(i.e. routine AHF). UF was inferior for the primary endpoint of
the bivariate change in the serum creatinine and body weight at
96 h due to an increase in creatinine. Whether such a rise in
serum creatinine represents desired effects of haemoconcentra-
tion or undesired WRF with subsequent outcome consequences
is unknown. There was no significant between-group difference
in weight loss or natriuretic peptides, and a higher percentage of
patients in the UF group had a serious adverse event. Overall, suc-
cessful decongestion (JVD <8 cm of water, ≤peripheral oedema,
no orthopnoea) occurred in only ∼10% of patients at 96 h in both
treatment arms. These data further demonstrate that substantial
weight and fluid loss are not adequate surrogates of decongestion.
UF use must also be balanced by limitations related to the tech-
nology. UF involves a disposable, single-use extracorporeal blood
circuit. A cost–consequences analysis found that despite a poten-
tial reduction in rehospitalization with UF, it was unlikely to result
in cost savings from a societal level.70 Despite the current ability to
perform UF through peripheral i.v. access, the lumens must pro-
vide 10–40 mL/min of blood flow such that patients are exposed
to increased risk related to vascular access complications. Full anti-
coagulation is required. In CARRESS-HF, patients receiving UF had
a high adverse event rate due to catheter- or anticoagulation-
related complications (e.g. 2% catheter site haemorrhage, 9% sep-
sis, bacteraemia, or cellulitis, and 7% gastrointestinal haemorrhage).
Provider experience and nursing support are additional concerns
with the routine use of UF.
Current guidelines indicate that if diuretic strategies are unsuc-
cessful, UF may be considered.1,3 The results of the ongoing
Study of Heart Failure Hospitalizations After Aquapheresis Therapy
Compared to Intravenous Diuretic Treatment (AVOID-HF, Clini-
calTrials.gov Identifier: NCT01474200) are eagerly awaited. This
trial is to enrol 810 patients admitted with AHF, and randomized
to either UF or i.v. loop diuretics. The primary outcome is time
to first HF event within 90 days after discharge from the index
hospitalization.
Vasopressin antagonists
Inappropriate elevation of AVP in HF results in water retention with
resultant congestive symptoms and electrolyte abnormalities.71
Vasopressin antagonists such as tolvaptan have been developed to
block the action of AVP at the V2 receptor in renal tubules to
promote aquaresis. V2-specific antagonists have the potential to
increase AVP levels with consequent stimulation of V1 receptors
involved in peripheral vasoconstriction. ..
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.. EVEREST was a large trial comparing tolvaptan and placebo,
which tested the hypothesis that adding an aquaretic agent to con-
ventional diuretics in HF patients would improve symptoms and
outcomes.72,73 EVEREST enrolled 4133 patients admitted with AHF
with EF <40% and ≥2 signs/symptoms of fluid overload. The pri-
mary short-term endpoint was a composite of patient-assessed
global clinical status and weight at day 7 or discharge. The long-
term co-primary endpoints were mortality and cardiovascular mor-
tality/HF hospitalization. Tolvaptan showed greater improvement
compared with placebo for weight change, but long-term outcomes
were similar.
In EVEREST, tolvaptan in addition to standard diuretic therapy
improved many, but not all, signs and symptoms related to conges-
tion. Tolvaptan improved dyspnoea, body weight, rales, JVD, and
orthopnoea over the first several days of hospitalization despite
less use of diuretics. However, global clinical status, a compo-
nent of the primary outcome, was not improved. The dyspnoea
benefits were greatest within 12 h after the initial dose, and per-
sisted up to 20 h74 (Figure 5). Tolvaptan’s benefits on dyspnoea
relief and weight reduction were more marked in those patients
with hyponatraemia.75 In the small cohort of patients with severe
hyponatraemia (sodium <130 mEq/L), tolvaptan was associated
with reduced cardiovascular morbidity and mortality. Overall, seri-
ous adverse events including renal dysfunction, hypotension, and
electrolyte abnormalities were similar with tolvaptan. These data
have suggested that tolvaptan may be a useful adjunct to treat-
ing congestion early during hospitalization in patients with AHF.
Tolvaptan is not specifically approved for treating congestion but
rather is approved for the treatment of severe hyponatraemia such
as that seen in heart failure. At present, at least two placebo-
controlled trials are exploring decongestion benefits with tolvaptan
in AHF (NCT01644331 and NCT01584557).
The Food and Drug Administration (FDA) recently announced
label changes for tolvaptan, which indicate that it should not be
used for longer than 30 days and should not be used in patients
with underlying liver disease. These changes were made after three
cases of suspected liver injury with higher doses and prolonged use
of tolvaptan were identified in the TEMPO study of patients with
Polycystic Kidney Disease.76
Natriuretic doses of mineralocorticoid
receptor antagonists
Chronic therapy with an MRA, either spironolactone 25 mg daily
or eplerenone 50 mg daily, is recommended in patients with NYHA
class II–IV symptoms and an LVEF ≤35%.1 A post-hoc analysis of
the EPHESUS study data suggested that eplerenone produced a
mild short-term diuretic effect associated with better outcomes.77
However, the benefits at these doses seem to be due largely
to cardioprotective effects rather than sodium handling.78 The
current evidence-based MRA doses in HF are much lower than the
natriuretic doses of up to 400 mg/day used in cirrhotic patients.79 It
has been suggested that natriuretic doses could provide additional
decongestion benefits beyond loop diuretics in AHF.79
In both cirrhosis and HF, hyperaldosteronism plays a major role
in the development of congestive symptoms and contributes to
© 2014 The Authors
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Figure 5 Improvement in patient-assessed dyspnoea with tolvaptan compared with placebo in EVEREST as a function of time from first dose
of study drug. Reproduced, with permission, from Pang et al. Eur Heart J 2009;30:2233–2240.74
diuretic resistance.39 The pathophysiology involves a failure to
escape from the sodium-retaining effect of aldosterone. Hyperal-
dosteronism increases the major aldosterone-sensitive renal tubule
channels.80 Therefore, sodium that is not reabsorbed in the loop
of Henle due to the effects of loop diuretics may be reabsorbed
in the distal nephron via aldosterone-related mechanisms. Natri-
uretic MRA doses in addition to loop diuretics may cause significant
natriuresis even in the context of presumed diuretic resistance. To
date, natriuretic MRA doses have not been empirically evaluated
in an adequately powered HF study. However, several small studies
have suggested potential benefits.81–84
The use of natriuretic MRA doses must be balanced with con-
cerns of hyperkalaemia. A recent retrospective study examined the
safety of natriuretic doses of spironolactone in HF patients.85 Dur-
ing a total of 738 patient-weeks, there was no significant increase in
mean serum potassium or creatinine with natriuretic MRA doses.
In contrast, a post-hoc analysis of the EPHESUS data suggested
that eplerenone produced a mild short-term potassium-sparing
effect, which was associated with better outcomes.77 Prospective,
controlled studies are needed to explore the benefits related to
decongestion.
Gut sequesterants
Since many patients with AHF have chronic kidney disease (CKD)
or WRF, it has been suggested that alternative, non-invasive strate-
gies to remove fluid should be explored.86 In particular, agents are
needed that assist with fluid removal without RAAS activation and
hyperkalaemia.
An acrylic polymer called cross-linked polyelectrolyte (CLP)
removes sodium, potassium, and fluid from the gastrointestinal
tract with elimination in the faeces. A double-blind randomized
trial of CLP vs. placebo for 8 weeks was performed in 113 HF
patients with CKD.87 There was no between-group difference in .
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.. the primary endpoint of serum potassium over time, but the CLP-
treated patients had greater weight loss early in the study as well as
improved symptoms and quality of life. There was a trend toward
less dyspnoea and lower natriuretic peptide levels with CLP. The
primary concern was that four deaths occurred in the CLP arm.
While this was a small study and investigators did not feel the
deaths were attributable to study drug, these findings highlight the
need for caution in subsequent studies. Future studies will need
to explore whether these potential benefits in weight loss, dysp-
noea relief, and natriuretic peptide levels translate into improved
decongestion in the setting of larger, controlled clinical trials.
Serelaxin
Serelaxin is recombinant human relaxin-2 peptide, which regulates
maternal adaptations in pregnancy.88 Serelaxin has potential bene-
fits for decongestion given effects on arterial compliance, cardiac
output, and renal blood flow.
The RELAX-AHF trial was a phase III placebo-controlled trial
of serelaxin in 1161 AHF patients with co-primary endpoints of
dyspnoea improvement.89 A 48-h infusion of serelaxin resulted in
an improvement in the visual analogue scale area under the curve
from baseline to 5 days, but not dyspnoea improvement by Lik-
ert scale. There were no between-group differences for secondary
composite endpoints including death or hospitalization. However,
all-cause mortality and cardiovascular mortality at 180 days were
significantly lower with serelaxin [hazard ratio (HR) 0.63, 95% con-
fidence interval (CI) 0.43–0.93; and HR 0.63, 95% CI, 0.41–0.96,
respectively]. Benefits with serelaxin were also observed for rates
of worsening HF, length of stay, and prognostic biomarkers.90 Sere-
laxin may offer benefits on congestion as evidence by effects on
dyspnoea relief and natriuretic peptides as well as the preven-
tion of worsening HF, but further study is required. The ongoing
RELAX-2 study is powered (target n = 6375) for the primary
© 2014 The Authors
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Figure 6 An approach to managing congestion in acute heart failure (HF) patients. MRA, mineralocorticoid receptor antagonist; SBP, systolic
blood pressure.
endpoint of cardiovascular mortality through 180 days (Clinical-
Trials.gov identifier: NCT01870778). A recent randomized study
investigated the renal haemodynamic effects of a 24-h infusion of
serelaxin vs. placebo in 65 patients with chronic HF.91 Serelaxin-
treated patients demonstrated a rise in renal plasma flow dur-
ing the infusion, but there was no between-group difference in
glomerular filtration rate. There were also no significant differences
for changes in systolic blood pressure (SBP) or sodium excre-
tion. Thus, ongoing study is required to investigate the mecha-
nisms by which serelaxin may improve symptoms and outcomes
in AHF.
Other novel agents under
investigation
In addition to gut sequesterants, serelaxin, and novel natriuretic
peptides such as ularitide, there are a number of additional AHF
therapeutic agents with potential decongestion benefits that are
currently under investigation. For instance, these agents include
luso-inotropic agents (istraoxime), cardiac myosin activators (ome-
camtiv mecarbil), and oral soluble guanylate cyclase stimulators,
which have recently been reviewed.17,68 Further studies will be
needed to clarify the utility of these and other agents with regard
to decongestion. .
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. Selecting an appropriate
decongestion approach
for different patients
Figure 6 outlines an approach to managing congestion in AHF
patients. An evidence-based initial approach to congestion manage-
ment involves high-dose i.v. diuretics by either i.v. bolus or contin-
uous infusion.44 Current guidelines indicate that the optimal dose
of i.v. furosemide is uncertain,3 but, based on DOSE-AHF, an initial
i.v. furosemide dose of 2.5 times the patient’s home oral diuretic
dose generally results in substantial diuresis and dyspnoea relief.
Diuretic dosing can be repeated as needed. Baseline electrolyte
abnormalities or renal dysfunction should lead to consideration
of other therapies including haemodiafiltration. In the subgroup of
AHF patients with elevation in SBP, the use of vasodilators may
be added for dyspnoea relief. In order to augment diuresis or to
overcome issues related to diuretic resistance, natriuretic MRA
doses may be used as long as the patient does not have significant
renal dysfunction or hyperkalaemia. Alternative strategies to aug-
ment decongestion include the use of thiazide-type diuretics39 or
potentially also vasopressin antagonists (particularly in the setting
of hyponatraemia).
In the setting of WRF, the CARRESS trial provided hypothesis-
generating evidence to support stepped pharmacological therapy
© 2014 The Authors
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to treat congestion.29 For the first 2 days, i.v. diuretics were
adjusted (± a thiazide diuretic) to manage congestion and main-
tain a urine output of 3–5 L/day. If after 48 h, urine output was
inadequate, the use of i.v. vasodilators or inotropic agents was con-
sidered. The specific protocols29 were dependent upon a patient’s
SBP, LVEF, and the presence or absence of RV failure. For instance,
if SBP was <110 mmHg and the patient had a reduced LVEF or RV
failure, then dopamine or dobutamine could be considered. If the
patient’s SBP was >120 mmHg and he/she had severe symptoms,
then nitroglycerin or nesiritide was considered. If urine output
was still inadequate after 72 h, then there was consideration for
haemodynamic-guided i.v. therapy, or crossover to UF or dialysis.
Importantly, this stepped pharmacological care algorithm has only
been compared with UF, and potential advantages over usual care
have not been empirically demonstrated.
If all diuretic strategies including consideration of stepped phar-
macological therapy are unsuccessful, then UF may be considered.
However, the results of CARRESS indicate that UF should be used
with caution in the setting of WRF. Alternatively, in AHF due to AF
and when i.v. inotropes are not feasible, digoxin may be considered.
In the future, options for decongestion therapy might also include
serelaxin and/or gut sequesterants.
Conclusion
Diuretics have been the mainstay of decongestion therapy. How-
ever, the approach to decongestion can be individualized based
on a patient’s initial diuretic response, co-morbidity burden, elec-
trolyte abnormalities, and haemodynamic profile. Different options
may include natriuretic MRA doses, vasodilators, and/or a stepped
pharmacological approach of diuretic up-titration and inotropes.
At the present time, the use of UF should be confined to patients
that fail to respond to diuretic-based strategies. In the future, gut
sequesterants and serelaxin may serve as additional or alternative
therapies. Although many unanswered questions remain about the
best approach for using these therapies, ongoing trials will inform
the future treatment of congestion.
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